Abstract WP347: Early Achievement of Blood Pressure Lowering on Hematoma Growth in Hyperacute Intracerebral Hemorrhage: the SAMURAI-ICH Study
Background: Little has been investigated about associations between timing of blood pressure lowering and clinical outcome of intracerebral hemorrhage (ICH).
Methods: The Stroke Acute Management with Urgent Risk-factor Assessment and Improvement (SAMURAI)-ICH Study is a multicenter, prospective, observational study investigating the safety and feasibility of early (within 3 hours from symptom onset) systolic blood pressure (SBP) reduction to less than 160 mmHg with intravenous nicardipine for acute hypertension in patients with spontaneous ICH. We retrospectively examined the relationship between time from onset, CT imaging, and initiation of antihypertensive treatment to target SBP achievement and hematoma growth in ICH patients. Hematoma growth was defined as an absolute growth of ≥ 6 ml from baseline to second imaging at 24 (±6) hours after the initiation of antihypertensive treatment.
Results: Among 211 patients (81 women (38.4%), mean age 66 years), mean baseline hematoma volume was 13 ml and hematoma growth was seen in 36 (17.1%) patients. Time from image to target SBP and time from treatment to target SBP were significantly shorter in patients without hematoma growth than those with (P = 0.043 and P = 0.032, respectively), whereas there was not significant difference in time from onset to target SBP between the two groups (P = 0.177). Lower quartiles of time from image to target SBP and time from treatment to target SBP had lower incidences of hematoma growth (P trend = 0.023 and 0.037, respectively, Cochran-Armitage test), whereas there was not significant trend in time from onset to target SBP (P = 0.074). The lowest quartile of time from image to target SBP was negatively associated with hematoma growth on multivariate logistic regression (odds ratio 0.182, 95% confidential interval 0.038-0.867, P = 0.032).
Conclusions: Early achievement to target SBP <160 mmHg was negatively associated with hematoma growth in ICH patients.
Author Disclosures: Y. Yamaguchi: None. M. Koga: None. K. Todo: None. S. Sato: None. H. Yamagami: None. K. Kamiyama: None. S. Okuda: None. Y. Okada: None. K. Kimura: None. Y. Shiokawa: None. E. Furui: None. Y. Hasegawa: None. K. Kario: None. S. Yoshimura: None. T. Ide: None. T. Yoshimoto: None. K. Nagatsuka: None. K. Toyoda: None.
- © 2017 by American Heart Association, Inc.